Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04873453 · ClinicalTrials.gov registry record · Phase 2
CBD for the Treatment of Alcohol Use Disorder
A Phase 2 study of Alcohol Use Disorder, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT04873453: Completed Phase 2 study of Alcohol Use Disorder, sponsored by University of Colorado, Denver.
NCT04873453 is a Phase 2 study of Alcohol Use Disorder that has completed, run by University of Colorado, Denver. The registered enrollment target is 45 participants, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04873453, a Phase 2 study of Alcohol Use Disorder, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a double-blind, placebo-controlled, parallel group study designed to assess the efficacy of full spectrum cannabidiol (CBD) and broad spectrum CBD, compared to a placebo control (PC), to reduce drinking in participants with moderate alcohol use disorder according to the DSM-V. If eligible for the study, subjects will be randomized to receive one of the conditions for 8 weeks.
Primary Outcome
The Time Line Follow Back is a calendar-assisted measure that can be used to assess alcohol, tobacco, cannabis, and other substance use. The investigators will use this measure to create the Drinks per Drinking Day variable.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Cannabidiol
Study Locations (1)
Colorado
- University of Colorado Denver - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2021-08-30 |
| Est. Completion | 2023-05-31 |
| Phase | Phase 2 |
What the finished NCT04873453 record still lists
NCT04873453 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Alcohol Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04873453 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT04873453 about?
NCT04873453 is a clinical study titled "CBD for the Treatment of Alcohol Use Disorder". This is a double-blind, placebo-controlled, parallel group study designed to assess the efficacy of full spectrum cannabidiol (CBD) and broad spectrum CBD, compared to a placebo control (PC), to reduce drinking in participants with moderate alcohol use disorder according to the DSM-V. If eligible fo...
What is the current status of trial NCT04873453?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2021-08-30. Estimated completion is 2023-05-31.
What conditions does trial NCT04873453 study?
This clinical trial studies the following conditions: Alcohol Use Disorder.
What interventions are being tested in trial NCT04873453?
The interventions under investigation include: Placebo (DRUG), Cannabidiol (DRUG).
Who is sponsoring clinical trial NCT04873453?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04873453 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04873453's enrollment target sits among peer trials
45 133rd of 184 higher than 51 of 184 other Alcohol Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcohol Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking
RECRUITING · Phase 2
-
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
RECRUITING · Phase 2
-
Psilocybin or Ketamine for Alcohol Use Disorder: An Active Comparator Trial
RECRUITING · Phase 2
-
Cannabis' Impact on Alcohol Consumption
RECRUITING · Phase 2
-
COMT Inhibition Among Individuals With Comorbid AUD/ADHD
RECRUITING · Phase 2
-
Semaglutide Therapy for Alcohol Reduction (STAR)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI